Edwards Lifesciences Corporation $EW Shares Sold by Strs Ohio

Strs Ohio trimmed its position in Edwards Lifesciences Corporation (NYSE:EW) by 5.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 122,821 shares of the medical research company’s stock after selling 7,603 shares during the quarter. Strs Ohio’s holdings in Edwards Lifesciences were worth $9,836,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. increased its position in Edwards Lifesciences by 27.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 109,749 shares of the medical research company’s stock worth $9,356,000 after purchasing an additional 23,514 shares during the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of Edwards Lifesciences by 39.6% during the 4th quarter. Assenagon Asset Management S.A. now owns 2,286,298 shares of the medical research company’s stock valued at $194,907,000 after buying an additional 648,870 shares during the last quarter. Central Pacific Bank Trust Division bought a new stake in shares of Edwards Lifesciences in the 4th quarter valued at approximately $775,000. Sivik Global Healthcare LLC bought a new stake in shares of Edwards Lifesciences in the 4th quarter valued at approximately $2,984,000. Finally, Stance Capital LLC increased its holdings in Edwards Lifesciences by 373.1% in the third quarter. Stance Capital LLC now owns 45,994 shares of the medical research company’s stock worth $3,577,000 after buying an additional 36,272 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $80.04, for a total value of $1,040,520.00. Following the transaction, the chief financial officer directly owned 39,699 shares in the company, valued at approximately $3,177,507.96. The trade was a 24.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $83.01, for a total value of $84,587.19. Following the transaction, the vice president directly owned 33,934 shares of the company’s stock, valued at $2,816,861.34. This represents a 2.92% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 57,958 shares of company stock valued at $4,839,284. Company insiders own 0.31% of the company’s stock.

Edwards Lifesciences Price Performance

NYSE EW opened at $94.31 on Monday. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $94.47. The company has a fifty day simple moving average of $85.61 and a 200 day simple moving average of $83.57. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. The company has a market cap of $54.31 billion, a P/E ratio of 50.17, a P/E/G ratio of 2.37 and a beta of 0.86.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.73 by $0.05. The firm had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business’s quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, sell-side analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on EW shares. Truist Financial set a $90.00 target price on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Monday, April 20th. Barclays reaffirmed an “overweight” rating and issued a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Wolfe Research raised shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price on the stock in a research report on Wednesday, April 1st. Finally, Evercore restated an “outperform” rating and set a $93.00 target price on shares of Edwards Lifesciences in a report on Friday, April 24th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $96.39.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.